SCIENCEDOMAIN international

www.sciencedomain.org



SDI Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_48724
Title of the Manuscript:	The Factors Related to Using Evidence-Based Guideline in Patients with Acute Ischemic Stroke
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that <u>NO</u> manuscript should be rejected only on the basis of '<u>lack of Novelty'</u>, provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline)

Created by: EA Checked by: ME Approved by: CEO Version: 1.6 (10-04-2018)

SCIENCEDOMAIN international www.sciencedomain.org



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	The Factors Related to Using Evidence-Based Guideline in Patients with Acute Ischemic Stroke	
	I read this manuscript and I think it could be an acceptable text if certain aspects are clarified and corrected.	
	The subject is interesting and important.	
	In any case, I congratulate the authors for their effort.	
	I suggest that, please, the authors verify the following comments:	
	-General comment:	
	The authors write in the Abstract: in 1396 ???	
	-Sample and sample size	
	Please provide a flowchart.	
	It seems that the sample size is calculated for the prevalence, but, was the sample size calculated for the comparison of the results between the groups? What were the hypothetical mean values or differences between groups, power, etc., to calculate the sample size?	
	The authors could provide all the statistical parameters of their samples.	
	-Discussion:	
	The review of the literature should be more than cite the results of other authors. It should be also be discussed the strengths and weaknesses of these studies, which should be provided a picture, albeit limited, of the state of knowledge and the main questions on the subject that these studies clarify and left unclear (e.g. by inadequate samples, incorrect design, testing erroneous statistics, characteristics of the persons studied, etc.).	
	-Conclusion:	
	It is important in any scientific paper to point out the problems that, from the current stud are still pending solution or clarification.	<mark>y,</mark>
	-References:	
	Review, please, the rules of the Journal.	

Created by: EA Checked by: ME Approved by: CEO Version: 1.6 (10-04-2018)

SCIENCEDOMAIN international www.sciencedomain.org



SDI Review Form 1.6

	The abbreviations of journals should conform to those of the US National Library of Medicine for Medline / PubMed (available in: https://www.ncbi.nlm.nih.gov/nlmcatalog/journals	
Minor REVISION comments		
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	

As per the guideline of editorial office we have followed VANCOUVER reference style for our paper.

Kindly see the following link:

http://sciencedomain.org/archives/20

Reviewer Details:

Name:	Jose Luis Turabian
Department, University & Country	Regional Health Service of Castilla la Mancha , Spain

Created by: EA Checked by: ME Approved by: CEO Version: 1.6 (10-04-2018)